Evaluating Thresholds to Adopt Hypofractionated Preoperative Radiotherapy as Standard of Care in Sarcoma.


Journal

Sarcoma
ISSN: 1357-714X
Titre abrégé: Sarcoma
Pays: Egypt
ID NLM: 9709257

Informations de publication

Date de publication:
2021
Historique:
received: 06 07 2021
accepted: 14 09 2021
entrez: 1 11 2021
pubmed: 2 11 2021
medline: 2 11 2021
Statut: epublish

Résumé

Data supporting hypofractionated preoperative radiation therapy (RT) for patients with extremity and trunk soft tissue sarcoma (STS) are currently limited to phase II single-institution studies. We sought to understand the type and thresholds of clinical evidence required for experts to adopt hypofractionated RT as a standard-of-care option for patients with STS. An electronic survey was distributed to multidisciplinary sarcoma experts. The survey queried whether data from a theoretical, multi-institutional, phase II study of 5-fraction preoperative RT could change practice. Using endpoints from RTOG 0630 as a reference, the survey also queried thresholds for acceptable local control, wound complication, and late toxicity for the study protocol to be accepted as a standard-of-care option. Responses were logged from 8/27/2020 to 9/8/2020 and summarized graphically. The survey response rate was 55.3% (47/85). Local control is the most important clinical outcome for sarcoma specialists when evaluating whether an RT regimen should be considered standard of care. 17% (8/47) of providers require randomized phase III evidence to consider hypofractionated preoperative RT as a standard-of-care option, whereas 10.6% (5/47) of providers already view this as a standard-of-care option. Of providers willing to change practice based on phase II data, most (78%, 29/37) would accept local control rates equivalent to or less than those in RTOG 0630, as long as the rate was higher than 85%. However, 51.3% (19/37) would require wound complication rates superior to those reported in RTOG 0630, and 46% (17/37) of respondents would accept late toxicity rates inferior to RTOG 0630. Consensus building is needed among clinicians regarding the type and threshold of evidence needed to evaluate hypofractionated RT as a standard-of-care option. A collaborative consortium-based approach may be the most pragmatic means for developing consensus protocols and pooling data to gradually introduce hypofractionated preoperative RT into routine practice.

Identifiants

pubmed: 34720663
doi: 10.1155/2021/3735874
pmc: PMC8556117
doi:

Types de publication

Journal Article

Langues

eng

Pagination

3735874

Informations de copyright

Copyright © 2021 Luca F. Valle et al.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

Eur J Surg Oncol. 2014 Dec;40(12):1641-7
pubmed: 25282099
Clin Cancer Res. 2020 Apr 15;26(8):1829-1836
pubmed: 32054730
J Clin Oncol. 1998 Jan;16(1):197-203
pubmed: 9440743
Lancet Oncol. 2020 Oct;21(10):1257-1258
pubmed: 32941793
Lancet Oncol. 2021 Jan;22(1):e2
pubmed: 33387501
J Clin Oncol. 2015 Jul 10;33(20):2231-8
pubmed: 25667281
J Grad Med Educ. 2011 Sep;3(3):285-9
pubmed: 22942950
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):1004-1015
pubmed: 29485042
Radiother Oncol. 2016 Apr;119(1):14-21
pubmed: 26718153
Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):1053-1063
pubmed: 33600887
Lancet. 2002 Jun 29;359(9325):2235-41
pubmed: 12103287
Lancet Oncol. 2021 Jan;22(1):e1
pubmed: 33387499
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67
pubmed: 29846498
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059428
Lancet Oncol. 2020 Oct;21(10):1366-1377
pubmed: 32941794
J Natl Compr Canc Netw. 2021 Feb 8;:1-12
pubmed: 33556919
Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):618-620
pubmed: 31540596
Adv Exp Med Biol. 2019;1123:95-118
pubmed: 31016597
J Clin Oncol. 2005 Oct 1;23(28):7074-80
pubmed: 16192590
Asia Pac J Oncol Nurs. 2017 Jan-Mar;4(1):69-76
pubmed: 28217733
Adv Radiat Oncol. 2020 Jun 29;5(6):1274-1279
pubmed: 33305088
J Natl Cancer Inst. 2000 Feb 2;92(3):269-71
pubmed: 10655446
Radiat Res. 2021 Jul 1;196(1):23-30
pubmed: 33914890
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):674-81
pubmed: 21277106

Auteurs

Luca F Valle (LF)

Department of Radiation Oncology, Jonsson Comprehensive Cancer Center and David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.

Nicholas Bernthal (N)

Department of Orthopedic Surgery, Jonsson Comprehensive Cancer Center and David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.

Fritz C Eilber (FC)

Departments of Surgery, Jonsson Comprehensive Cancer Center and David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.

Jacob E Shabason (JE)

Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.

Meena Bedi (M)

Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.

Anusha Kalbasi (A)

Department of Radiation Oncology, Jonsson Comprehensive Cancer Center and David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.

Classifications MeSH